GEHC Stock Chart & Stats
$1240.88
$0.61(0.06%)
At close: 4:00 PM EDT
$1240.88
$0.61(0.06%)
Day’s Range― - ―
52-Week Range$1,020.11 - $1,709.97
Previous CloseN/A
Volume0.00
Average Volume (3M)49.00
Market Cap
$497.55B
Enterprise Value$37.74K
Total Cash (Recent Filing)$2.10B
Total Debt (Recent Filing)$10.09B
Price to Earnings (P/E)18.4
Beta0.59
Next Earnings
Nov 04, 2026EPS Estimate
20.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.48
Shares Outstanding451,686,250
10 Day Avg. Volume140
30 Day Avg. Volume49
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,355.40Price Target Upside9.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)83.64
Revenue Forecast (FY)$368.82B
Bulls Say, Bears Say
Bulls Say
Backlog And Recurring Service StrengthStrong bookings and a record backlog improve forward revenue visibility, while service growth adds recurring income tied to the installed base. This combination supports steadier execution and reduces reliance on individual capital-equipment purchases over the next several quarters.
Pharmaceutical Diagnostics GrowthPharmaceutical Diagnostics is showing both strong demand and attractive profitability, providing an important growth engine beyond equipment sales. Flyrcado adoption also creates a platform for expanding recurring radiopharmaceutical revenue and supports the company’s longer-term product mix.
AI-enabled Software ExpansionLaunching an AI-enabled SaaS product broadens GEHC’s offering from hardware into operational software with potential for recurring revenue and deeper customer integration. Early deployments at major health systems can provide validation and support adoption across hospital networks.
Bears Say
Patient Care Solutions WeaknessPCS represents a material execution and portfolio challenge because falling revenue and negative EBIT directly pressure consolidated profitability. The strategic review signals that management may need significant corrective action before the segment can become a dependable contributor.
Margin Pressure From InflationPersistent component, memory, oil, and freight inflation can erode profitability even when demand remains healthy. Although management expects pricing and cost actions to help, continued cost pressure raises execution risk and makes the targeted margin expansion harder to sustain.
Weaker Free Cash FlowThe decline in free cash flow reduces internally generated funding for innovation, acquisitions, debt reduction, and shareholder returns. Positive cash generation remains intact, but weaker conversion and modest operating cash flow relative to revenue make financial flexibility less robust.
GE Healthcare Technologies Inc News
GEHC FAQ
What was GE Healthcare Technologies Inc’s price range in the past 12 months?
GE Healthcare Technologies Inc lowest stock price was $1020.11 and its highest was $1709.97 in the past 12 months.
What is GE Healthcare Technologies Inc’s market cap?
GE Healthcare Technologies Inc’s market cap is $497.55B.
When is GE Healthcare Technologies Inc’s upcoming earnings report date?
GE Healthcare Technologies Inc’s upcoming earnings report date is Nov 04, 2026 which is in 49 days.
How were GE Healthcare Technologies Inc’s earnings last quarter?
GE Healthcare Technologies Inc released its earnings results on Jul 29, 2026. The company reported $19.183 earnings per share for the quarter, beating the consensus estimate of $17.588 by $1.596.
Is GE Healthcare Technologies Inc overvalued?
According to Wall Street analysts GE Healthcare Technologies Inc’s price is currently Undervalued.
Does GE Healthcare Technologies Inc pay dividends?
GE Healthcare Technologies Inc does not currently pay dividends.
What is GE Healthcare Technologies Inc’s EPS estimate?
GE Healthcare Technologies Inc’s EPS estimate is 20.44.
How many shares outstanding does GE Healthcare Technologies Inc have?
GE Healthcare Technologies Inc has 451,686,250 shares outstanding.
What happened to GE Healthcare Technologies Inc’s price movement after its last earnings report?
GE Healthcare Technologies Inc reported an EPS of $19.183 in its last earnings report, beating expectations of $17.588. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of GE Healthcare Technologies Inc?
Currently, no hedge funds are holding shares in MX:GEHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GE Healthcare Technologies Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,355.40 (9.23% Upside)
$1,355.40 (9.23% Upside)
Blogger Sentiment
Bullish
MX:GEHC Sentiment 89%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.44%
12-Months-Change
Fundamentals
Return on Equity
0.23%
Trailing 12-Months
Asset Growth
4.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GE Healthcare Technologies Inc
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
GEHC Company Deck
GEHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed strong commercial momentum: record orders, backlog, solid revenue growth, PDx outperformance, AIS margin expansion, and progress on new AI-enabled products and Flyrcado ramp. Offsetting these positives were meaningful near-term challenges in Patient Care Solutions (13.5% organic decline and negative segment EBIT), inflationary headwinds (memory, oil, freight), and cash volatility driven by tariff refunds. Management maintained full-year guidance and reiterated medium-term targets, expressing confidence in recovery actions and the innovation pipeline.View all MX:GEHC earnings summariesGEHC Revenue Breakdown
44.82% Imaging
25.96% AVS
14.96% PCS
14.06% PDx
0.19% Other
GEHC Stock 12 Month Forecast
Average Price Target
$1,355.40
▲(9.23% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Koninklijke Philips
―
Medtronic
―